Second-Ever Therapy for Waldenström’s Macroglobulinemia is Now FDA Approved
source: pixabay.com

Second-Ever Therapy for Waldenström’s Macroglobulinemia is Now FDA Approved

The FDA has just announced their approval of zanubrutinib (Brukinsa) as a therapeutic option for Waldenström's macroglobulinemia. This approval was given based on the ASPEN Phase 3 clinical trial, and…

Continue Reading Second-Ever Therapy for Waldenström’s Macroglobulinemia is Now FDA Approved
Waldenström’s Macroglobulinemia Precursor States: Could They be Key to a Cure?
source: pixabay.com

Waldenström’s Macroglobulinemia Precursor States: Could They be Key to a Cure?

On October 14th, 2020, the International Waldenström's Macroglobulinemia Foundation (IWMF) hosted a webinar featuring Dr. Irene Ghobrial of the Dana Farber Cancer Institute. The focus of her presentation was on…

Continue Reading Waldenström’s Macroglobulinemia Precursor States: Could They be Key to a Cure?
September 15th is World Lymphoma Awareness Day: Spreading Blood Cancer Awareness
source: pixabay.com

September 15th is World Lymphoma Awareness Day: Spreading Blood Cancer Awareness

September 15th, 2020 is recognized as World Lymphoma Awareness Day. This day is dedicated to spreading awareness about lymphoma and falls in the context of Blood Cancer Awareness Month, which…

Continue Reading September 15th is World Lymphoma Awareness Day: Spreading Blood Cancer Awareness
Investigational Waldenström’s Macroglobulinemia Treatment Earns Orphan Drug Designation
source: pixabay.com

Investigational Waldenström’s Macroglobulinemia Treatment Earns Orphan Drug Designation

According to a story from BioSpace, the biotechnology company Ascentage Pharma has just announced that it has been given Orphan Drug designation from the US Food and Drug Administration (FDA).…

Continue Reading Investigational Waldenström’s Macroglobulinemia Treatment Earns Orphan Drug Designation
IWMF and PleXus Communications are Teaming up to Help Spread Waldenstrom’s Macroglobulinemia Awareness
Nappiness / Pixabay

IWMF and PleXus Communications are Teaming up to Help Spread Waldenstrom’s Macroglobulinemia Awareness

The International Waldenstrom's Macroglobulinemia Foundation (IWMF) has recently announced an exciting new partnership that will help facilitate spreading awareness about Waldenstrom's macroglobulinemia (WM), a rare form of blood cancer. This…

Continue Reading IWMF and PleXus Communications are Teaming up to Help Spread Waldenstrom’s Macroglobulinemia Awareness

Saturday Afternoon Live: Dr. Steven Treon’s Presentation at the 2019 IWMF Educational Forum June 8th will be Streamed Online!

The International Waldenstrom's Macroglobulinemia Foundation (IWMF) is a nonprofit organization founded by patients. Their mission? Support patients currently living with Waldenstrom's Macroglobulinemia (WM) while simultaneously supporting the search for a…

Continue Reading Saturday Afternoon Live: Dr. Steven Treon’s Presentation at the 2019 IWMF Educational Forum June 8th will be Streamed Online!

First Chemotherapy-Free Combination Treatment Approved For Waldrenstrom’s Macroglobulinemia

According to a story from BioSpace, the biopharmaceutical company AbbVie recently announced that the US Food and Drug Administration (FDA) has approved a new combination treatment for Waldenstrom's macroglobulinemia (WM).…

Continue Reading First Chemotherapy-Free Combination Treatment Approved For Waldrenstrom’s Macroglobulinemia
A Patient With Waldenström Macroglobulinemia has Shown a Large Reduction in Overall Tumour Volume While Taking Part in a Clinical Trial
valelopardo / Pixabay

A Patient With Waldenström Macroglobulinemia has Shown a Large Reduction in Overall Tumour Volume While Taking Part in a Clinical Trial

A patient with Waldenström Macroglobulinemia taking part in a clinical trial of the experimental drug CLR 131 for the treatment of B-cell hematologic cancers is reported to have achieved a…

Continue Reading A Patient With Waldenström Macroglobulinemia has Shown a Large Reduction in Overall Tumour Volume While Taking Part in a Clinical Trial